focus -WSS

focus

author：hotspot 2025-10-02 22:56:10 - browse：17545

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Plastic surgeons increase patient psychiatric screenings

Wikipedia

WSS

Humana, CVS hope to turn members into patients at clinics

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

ProMED, early warning system on disease outbreaks, in peril

Gene editing the human germline: What are the risks?

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Positive childhood experiences can help future health

Wikipedia

focus

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Intermittent fasting comes with a heart risk? Not so fast

Virginia high school admissions case could be legal follow

Verily hires former Apple Health leader as chief scientific officer

Medical records are filled with copy

Positive childhood experiences can help future health

Heart attack and stroke risk calculators need revising

Health AI adoption puts security, privacy startups on investors' radar

Novavax promises a turnaround & Lilly roils the obesity market

Nearly two

hotspot

Plastic surgeons increase patient psychiatric screenings

Dramatically reducing cancer deaths requires the PASTEUR Act

Creating egg and sperm cells from stem cells raises ethical issues

Positive childhood experiences can help future health

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Orchard's therapy for neuron disease in children wins FDA approval

focus

Wikipedia

hotspot

explore